Mostrando 10 resultados de: 18
Filtros aplicados
Publisher
Pharmacogenomics Journal(4)
Drug Metabolism and Drug Interactions(3)
Pharmacogenomics(3)
OMICS A Journal of Integrative Biology(2)
CYP2D6: Genetics, Pharmacology and Clinical Relevance(1)
Área temáticas
Bioquímica(6)
Medicina y salud(6)
Fisiología humana(4)
Enfermedades(3)
Salud y seguridad personal(2)
Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 ethnic variability in hispanics
Book PartAbstract: Genetic polymorphism in the CYP2D6 gene results in a wide variability in CYP2D6 enzymatic activity,Palabras claves:Autores:Adrián LLerena, Dorado P., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 gene polymorphisms and pbkp_redicted phenotypes in eight indigenous groups from northwestern Mexico
ArticleAbstract: Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficienPalabras claves:allele frequency, CYP2D6polymorphism, Mexican indigenous, pbkp_redicted phenotype, pharmacogeneticsAutores:Adrián LLerena, Galaviz-Hernandez C., Garza-Veloz I., Lazalde-Ramos B.P., Martínez-Fierro M.L., Naranjo M.E.G., Sosa-Macías M.G.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusErratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (Molecular Psychiatry (2013) 18 (266))
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Alonso E., Dorado P., Jung H., López-López M., Naranjo M.E.G., Ortega A., Penãs-Lledó E.M., Trejo H.D.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusHigh frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopusHigh frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
ArticleAbstract: A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was repPalabras claves:Autores:Adrián LLerena, Dorado P., Ferreiro V., Moya G.E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopus